Bempedoic Acid 180 mg vs Placebo Comparator: Number of Participants With First Occurrence of Four Component Major Adverse Cardiovascular Events (MACE)

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

Measures 6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

Measure	Value	95% interval, lower	95% interval, upper	Method	Source
Risk in group 1	0.117	0.11	0.125	wilson	ClinicalTrials.gov
Risk in group 2	0.133	0.125	0.141	wilson	ClinicalTrials.gov
Risk difference, group 1 minus group 2	-0.0157	-0.0267	-0.00474	newcombe hybrid score	ClinicalTrials.gov
Risk ratio, group 1 over group 2	0.882	0.807	0.963	log	ClinicalTrials.gov
Odds ratio, group 1 over group 2	0.866	0.783	0.958	log	ClinicalTrials.gov
Number needed to treat, for one fewer participant with the outcome on Bempedoic Acid 180 mg than on Placebo Comparator	63.6	37.5	211	from the risk difference interval	ClinicalTrials.gov

Groups 2

Group 2 names the comparator: placebo.

Group	Title	Description	With the outcome	Analysed	ClinicalTrials.gov code	Source
Group 1	Bempedoic Acid 180 mg	Participants were administered with Bempedoic acid 180 mg tablet once daily orally.	819	6,992	OG000	ClinicalTrials.gov
Group 2	Placebo Comparator	Participants were administered with matching Placebo tablet once daily orally.	927	6,978	OG001	ClinicalTrials.gov

Outcome 5

Field	Value	Source
Type	PRIMARY	ClinicalTrials.gov
Title	Number of Participants With First Occurrence of Four Component Major Adverse Cardiovascular Events (MACE)	ClinicalTrials.gov
Description	The primary efficacy end point was a four-component composite of adjudicated MACE, defined as death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization, as assessed in a time-to first-event analysis.	ClinicalTrials.gov
Time frame	Up to 68 months	ClinicalTrials.gov
Population	Intention-to-Treat Population.	ClinicalTrials.gov

Trial 8

Field	Value	Source
Title	Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo	ClinicalTrials.gov
NCT number	NCT02993406	ClinicalTrials.gov
Phases	PHASE3	ClinicalTrials.gov
Conditions	Cardiovascular Diseases, Statin Adverse Reaction	ClinicalTrials.gov
Interventions	Bempedoic acid 180 mg tablet, Matching placebo tablet	ClinicalTrials.gov
Lead sponsor	Esperion Therapeutics, Inc.	ClinicalTrials.gov
Results first posted	2024-01-03	ClinicalTrials.gov
Results on ClinicalTrials.gov	https://clinicaltrials.gov/study/NCT02993406?tab=results	ClinicalTrials.gov

Source 4

Field	Value	Source
Release	trial-comparisons-2026-03-23-0.1.0	ClinicalTrials.gov
Release manifest SHA-256	f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57	ClinicalTrials.gov
AACT copy	2026-03-23	ClinicalTrials.gov
Tables read	outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet	ClinicalTrials.gov

The same record as JSON

Release trial-comparisons-2026-03-23-0.1.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.